Kay Kelts, DO
Family Medicine · Rapid City, SDNPI 1083956932
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$620
- Amgen$598
- Lilly USA, LLC$458
- AbbVie$328
- Bayer$321
- Novo Nordisk$314
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,592100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 15 | $620 |
| Amgen | 46 | $598 |
| Lilly USA, LLC | 44 | $458 |
| AbbVie | 13 | $328 |
| Bayer | 14 | $321 |
| Novo Nordisk | 22 | $314 |
| Novartis | 14 | $229 |
| Boehringer Ingelheim | 8 | $227 |
| GSK | 11 | $200 |
| Pfizer | 11 | $172 |
| Exact Sciences | 10 | $149 |
| Madrigal Pharmaceuticals | 1 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| Inspire Medical Systems, Inc. | 2 | $86 |
| Merck | 4 | $65 |
| Daiichi Sankyo Inc. | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Amarin Pharma, Inc. | 3 | $47 |
| Johnson & Johnson | 3 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Grifols USA, LLC | 2 | $40 |
| Dexcom, Inc. | 1 | $38 |
| Indivior Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $35 |
| Redhill Biopharma Inc. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Medtronic | 2 | $29 |
| Abbott | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,606 in reported general payments places this provider in the 95th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 147 | $185,969 |
| EliquisApixaban | 85 | $107,297 |
| OzempicSemaglutide | 38 | $68,040 |
| JardianceEmpagliflozin | 33 | $42,758 |
| XareltoRivaroxaban | 27 | $38,987 |
| TrulicityDulaglutide | 16 | $27,212 |
| RybelsusSemaglutide | 18 | $22,210 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $18,628 |
| OxycontinOxycodone Hcl | 12 | $15,652 |
| FarxigaDapagliflozin Propanediol | 13 | $12,221 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,266 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $7,542 |
| Omeprazole | 330 | $4,505 |
| Levothyroxine Sodium | 506 | $4,362 |
| Atorvastatin Calcium | 480 | $4,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $458 | $213,181163 claims |
| PfizerEliquis | $172 | $107,29785 claims |
| Novo NordiskOzempic, Rybelsus | $314 | $90,25056 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $227 | $50,30046 claims |
| Johnson & JohnsonXarelto | $47 | $38,98727 claims |
| GSKTrelegy Ellipta | $200 | $18,62815 claims |
| AstraZenecaFarxiga, Symbicort | $620 | $15,32126 claims |
| AbbVieSynthroid, Armour Thyroid | $328 | $5,21885 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Rapid City
- Kyla Helm-SwansonRapid City$22K
- Kinsey Shultz PiatzRapid City$5K
- Egon DzintarsRapid City$4K
- Erika ToyodaRapid City$2K
- Carol ZielikeRapid City$2K
- Lorelee StockRapid City$2K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Michael GerlachMitchell$9K
- Jeffry MeyerSioux Falls$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.